
Biogen’s Bold Bet: A New Hope for Dravet Syndrome Shines Bright
Biogen and Stoke Therapeutics have formed a multi-million dollar collaboration to develop treatments for Dravet syndrome. The focus of their partnership is zorevunersen, an investigational therapy targeting the SCN1A gene, implicated in most Dravet cases. Stoke plans to initiate a Phase 3